<SEC-DOCUMENT>0001019687-13-000033.txt : 20130104
<SEC-HEADER>0001019687-13-000033.hdr.sgml : 20130104
<ACCEPTANCE-DATETIME>20130104093107
ACCESSION NUMBER:		0001019687-13-000033
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130103
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130104
DATE AS OF CHANGE:		20130104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AETHLON MEDICAL INC
		CENTRAL INDEX KEY:			0000882291
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				133632859
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21846
		FILM NUMBER:		13509917

	BUSINESS ADDRESS:	
		STREET 1:		8910 UNIVERSITY CENTER LANE, SUITE 660
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122
		BUSINESS PHONE:		858-459-7800

	MAIL ADDRESS:	
		STREET 1:		8910 UNIVERSITY CENTER LANE, SUITE 660
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BISHOP EQUITIES INC
		DATE OF NAME CHANGE:	19930602
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>aethlon_8k.htm
<DESCRIPTION>CURRENT REPORT ON FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 8-K</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Section&nbsp;13 or 15(d)&nbsp;of
the Securities Exchange Act of 1934</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Date of Report (Date of earliest event reported):
January 3, 2013</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AETHLON MEDICAL, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified in its
charter)</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 32%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 32%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 32%; font-size: 10pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Nevada</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(State or other jurisdiction</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">of incorporation)</P></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">000-21846</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Commission File Number)</P></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">13-3632859</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(IRS Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Identification Number)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 55%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 42%; font-size: 10pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">8910 University Center Lane, Suite 660</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">San Diego, California</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of principal executive offices)</P></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">92122</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Zip Code)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: (858) 459-7800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Not applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Former name or former address, if changed since
last report.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2 below):</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 97%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">FORWARD LOOKING STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 45.8pt">This Form 8-K and other reports filed by Registrant
from time to time with the Securities and Exchange Commission (collectively the &quot;Filings&quot;) contain or may contain forward
looking statements and information that are based upon beliefs of, and information currently available to, Registrant's management
as well as estimates and assumptions made by Registrant's management. When used in the Filings the words &quot;anticipate, &quot;believe&quot;,
&quot;estimate&quot;, &quot;expect&quot;, &quot;future&quot;, &quot;intend&quot;, &quot;plan&quot; or the negative of these terms
and similar expressions as they relate to Registrant or Registrant's management identify forward looking statements. Such statements
reflect the current view of Registrant with respect to future events and are subject to risks, uncertainties, assumptions and other
factors relating to Registrant's industry, Registrant's operations and results of operations and any businesses that may be acquired
by Registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect,
actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 45.8pt">Although Registrant believes that the expectations
reflected in the forward looking statements are reasonable, Registrant cannot guarantee future results, levels of activity, performance
or achievements. Except as required by applicable law, including the securities laws of the United States, Registrant does not
intend to update any of the forward-looking statements to conform these statements to actual results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 7.01 Regulation FD Disclosure.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On January 3, 2013, the Registrant disclosed
through a press release that it submitted an Investigational Device Exemption to the U.S. Food and Drug Administration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The press release is attached hereto as
Exhibit 99.1. &nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Limitation on Incorporation by Reference</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In accordance with General Instruction B.2 of Form 8-K, the information
in this Item 7.01 shall not be deemed &ldquo;filed&rdquo; for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference
in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such
a filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 9.01 Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 83px">&nbsp;</TD>
    <TD STYLE="width: 17px">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; font-weight: bold">Exhibit No.:</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; font-weight: bold">Description:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 13.8pt">99.1</TD>
    <TD>&nbsp;</TD>
    <TD>Press release issued January 3, 2013</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 46%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 48%">&nbsp;AETHLON MEDICAL, INC.</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: white 3pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: white 3pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: white 3pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: white 3pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">By:&nbsp;<U>/s/ James A. Joyce</U></P></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">James A. Joyce</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Dated: January 4, 2013</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>aethlon_8k-ex9901.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 99.1</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><IMG SRC="image_001.jpg" ALT="aethlon_logo" STYLE="height: 72px; width: 193px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 3pt; text-align: center"><B>Aethlon Medical Discloses Submission
of Hepatitis C Virus (HCV) IDE to FDA </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 3pt; text-align: justify"><B>SAN DIEGO &ndash; January 3, 2013
&ndash; Aethlon Medical, Inc.</B> (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address
infectious disease, cancer and other life-threatening conditions, disclosed today that it has submitted an Investigational Device
Exemption (IDE) to the U.S. Food and Drug Administration (FDA) that requests permission to initiate a clinical feasibility study
of Hepatitis-C (HCV) infected individuals enrolled to receive Hemopurifier&reg; therapy. Upon approval by FDA, an IDE allows an
investigational device to be used in a clinical study in order to collect safety and effectiveness data required to support a Premarket
Approval (PMA) application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 3pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 3pt; text-align: justify">The Aethlon Hemopurifier&reg; is a first-in-class
medical device that targets the rapid clearance of HCV from the entire circulatory system. The goal of therapy is to improve the
benefit of interferon-based or all-antiviral HCV drug regimens. Aethlon&rsquo;s IDE submission included clinical data from Hemopurifier&reg;
studies of HCV-infected individuals conducted at the Apollo Hospital, Fortis Hospital, and the Medanta Medicity Institute, all
located in India. As requested by FDA during a Pre-IDE meeting, Aethlon also provided data that quantified the capture of HCV within
the Hemopurifier&reg; during treatment. The proposed feasibility study would enroll 10 patients with End Stage Renal Disease (ESRD)
and concomitant HCV infection. The study would be conducted by the Renal Research Institute (RRI), which was established in 1997
as a partnership between Fresenius Medical Care (FMC) and Beth Israel Medical Center, New York City.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About Aethlon Medical</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Aethlon Medical creates innovative medical
devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT&trade;
System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal
of disease promoting particles from the entire circulatory system. &nbsp;At present, The Aethlon ADAPT&trade; product pipeline
includes the Aethlon Hemopurifier&reg; to address infectious disease and cancer, and a medical device being developed under a 5-year
contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers. For
more information, please visit <FONT STYLE="text-underline-style: none; color: windowtext">www.aethlonmedical.com</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About The Aethlon Hemopurifier&reg;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Aethlon Hemopurifier&reg; is a first-in-class
medical device that selectively targets the rapid clearance of infectious viral pathogens and immunosuppressive proteins from the
entire circulatory system.&nbsp; In the treatment of Hepatitis C virus (HCV), human studies have demonstrated that Hemopurifier&reg;
therapy may improve immediate, rapid and sustained virologic response rates when administered in the first few days of standard-of-care
drug therapy.&nbsp;&nbsp; In addition to accelerating viral load depletion, post-treatment analysis of the Hemopurifier&reg; has
documented the capture of up to 300 billion HCV copies of HCV during a single six-hour treatment. Access to Hemopurifier&reg; therapy
is available on a compassionate-use basis through the Medanta Medicity Institute (Medicity), a leading center for medical tourism
in India.&nbsp; The Medicity is offering treatment access to infected individuals who previously failed or subsequently relapsed
standard-of-care drug regimens.&nbsp; The Hemopurifier&reg; is also being offered as a salvage therapy to infected individuals
who suffer a viral breakthrough during standard-of-care therapy. U.S. studies of the Hemopurifier&reg; are currently pending approval
of an IDE submitted to FDA.</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>The Aethlon Hemopurifier&reg; and Cancer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to the opportunity to address a
broad-spectrum of infectious viral pathogens, the Hemopurifier&reg; has been discovered to capture tumor-derived exosomes underlying
several forms of cancer.&nbsp; Tumor-derived exosomes have recently emerged to be a vital therapeutic target in cancer care. These
microvesicular particles suppress the immune response in cancer patients through apoptosis of immune cells and their quantity in
circulation correlates directly with disease progression. Beyond possessing immunosuppressive properties, tumor-derived exosomes
facilitate tumor growth, metastasis, and the development of drug resistance. &nbsp;By addressing this unmet medical need, the Hemopurifier&reg;
is positioned as an adjunct to improve established cancer treatment regimens.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Certain statements herein may be forward-looking
and involve risks and uncertainties.&nbsp; Such forward-looking statements involve assumptions, known and unknown risks, uncertainties
and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different
from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks
and uncertainties include, without limitation, that the FDA will not approve the initiation of the Company's clinical programs
or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating from either
compassionate use or non-compassionate use of the Aethlon ADAPT&trade; system or the Aethlon Hemopurifier&reg; as an adjunct therapy
to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy,
the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products,
the Company's ability to manufacture its products either internally or through outside companies and provide its services, the
impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty
of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ
materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions
and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation
to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"># # #</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Contacts:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">James A. Joyce</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Chairman and CEO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">858.459.7800 x301</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">jj@aethlonmedical.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Jim Frakes</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">858.459.7800 x300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">jfrakes@aethlonmedical.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Marc Robins</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">877.276.2467</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">mr@aethlonmedical.com</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!PD'!@H)"`D+"PH,#QD0#PX.
M#QX6%Q(9)"`F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$!`)C!&2T4^2CD_0#W_
MVP!#`0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P``1"`!(`,$#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHI*`%J.:>*WB:6:1(XU&69S@#\:H:
M]KMKX?T]KJZ))/RQQK]Z1O0?XUX_KOB._P#$%P7O),1`_)`I^1/P[GW-=F%P
M<\1KLNYSUL1&EINST;4/B/HMFS)`9;QAWB7Y?S./TK*;XK19^729"/><`_RK
MSFBO6CEM!+57^9PO%U7LSU*S^)^ES,%NK:YML_Q8#C].?TKJ]/U.SU2#SK&Y
MCGC[E#G'U':O`JL6-_<Z;=+<V4[PS+_$IZ^Q'<>QK*KE=-K]V[,TAC)+XM3W
M^EKEO"'C&+Q!$;>X"Q7\:Y9!TD']Y?ZBNIKQ:E.5.3C):GH0FIKFB%%%%04%
M%0W=Y;V%K)<WD\<$$8R\DC!54>Y-<VWQ-\())L.NVV?4!B/S`Q0!U5%5;#4K
M/5;1;K3[F*YMWZ21,&!JE>^*=&TZX,%WJ,$<J]4W9(^N.E5&,I.T5<3DH[LU
MZ*SUUS37TV34%OH#9Q#=),'&U![^E<3X<^*]CJ&M:S%J]]I]I9VTH2R<,1YR
MY;YLD\\!>F.M)IIV8)WV/1J*\M\7:G))\5O"'V.[D-I<HCXCD(212Q(.!P<B
MNNO/B)X5L+IK>XUNU$JG:P4EP#[D`BD,Z2BJVGZC9ZK:)=:?<Q7-N_W9(F#`
MUYW\-KNXN/'OC..:XFDCBN<1H[E@@\R3H#TH`]-HK-UCQ%I.@1J^K7\%H'^Z
M)&P6^@ZFJFD^-_#NN7(M]-U:VFG/W8\E6;Z!L$_A0!NT54U+5;+1[-KO4;F.
MVMU(4R2'`!/2L[4O&OA[1UB:_P!6MH?.02(N[<S*1D'`R<&@#<IKL$4LQ`4#
M))["LS1O$^C>(0_]DZC;W10994;YE'J5/-5/'-\UAX3O&0D/*!"I'^T<'],U
M=.#G)174F4N6+D>8>*==?7]9DGW'[/&2D"^B^OU/6JFDZ/>ZW>?9K"+S)`NY
MB3A5'J35'H*]C\#Z!_8FAHTR8NKG$DN>H_NK^`_4FOH<36CA**4-]D>51@Z\
M[R^9PW_"N-?_`.>=M_W^_P#K4?\`"N-?_P">=M_W^_\`K5Z[7'_$[Q;_`,(I
MX5E>!]M]=YAML=5./F?\!^I%>9_:=?R.WZG3/,+^PN=,O)+2\B,4\?WE/Z$'
MN*KT_0-7E\4>'I8+N5YM4TI?,1W.7FMB>03U)0G/T/M3*]?"XA5Z:EUZGGUJ
M7LY\I-:74UC=Q7-LY2:)@R,.QKW'0M6CUO1[>^B`'FK\R_W6'!'YUX17HOPK
MOF,=_8L>%*S(/3/!_D*YLSHJ5/VBW7Y&V#J<L^7N>AT445X!ZA2U:VL+O39H
MM66![+`:59R`F`01NSQC('6N/N_'/A"&-M/TNS75I2,"TL+/S%;MC.-N*S?C
M;'.VGZ,\JSMI"76;X19Z?+C/X;\>YKH]!\5>#(8[2PT.]L8_/98XH($(8D],
MC&<^YH`\Z\`:G<:/X9\8/%&;21+E$2$'(@9BRD#W'3\!79^&-1TS1](A3^R-
M3EN)%WS3"R+>8QY/S=QZ5S?@?2CK4?CRR0@227V8R>FX/(1^HKKO#WC*RL=.
MBT[79&L+VT41,LRD!@.`0?I7;2UHM15W?6WX'-4TJ7;MH4-.ACN?'+&UTJYB
MTJ^A*W4-Q:E8V;!/*GCL/S-8WPWT32[WQ?XQANM-LYXH+S;$DD"LL8WR<*".
M!P.GI7HVF>)M,UF\>VTZX^T-&F]V53M`SCJ:\O\`"GBG3/!WC_Q=#KTKV?VF
MZ+QLT;,#AW/8$\A@16%>3E)<RM9&E**2T=Q?BCIAO?B-X8TVT<VJRPK`K1?+
MY:%R#MQTP,UZ-;^!O#=MIPLDT6Q,.W:=\(9C[ECSGWS7!^+;R+4/BOX)N[=B
MT,\4<L9(QE68D''T->M5B:GE7PG@&D>,_%NC6[O]BMYAY:,<XPS#\\8'X"G_
M``R(7X@>.">@NL_^1)*=\//^2I^-?^NQ_P#1C4WX8X/Q!\;@][K_`-J24`0?
M#G3+?QQK.L>*==A6\D%SY-K%,-R1*!GA3QP"`/Q/4UN?$OP;I=UX4O=1MK2&
MUO[",W$4\""-OEY(..O`/T.*Y_PWJ:?"KQ#JFCZ\DL6E7<WGV=X(RR>F#CVP
M#Z$>AS5_QM\0M/US19M`\+-)JFHZ@ODX@C;:B'[Q)(]./;.30!G^*];D\0_`
M6VU"X;=.[QI*WJRN5)_'&?QKIO`G@C2X/#5E>ZE907VHWD"333W*"0C*C"C.
M<`+@<>E8/CG0_P#A&_@?!I;,&D@:+S&7H7+Y;'XDUZ+X;_Y%C2O^O.'_`-`%
M`'F.NZ5:>%OC1X=DT:%;1;[`FBB&U#DE3@=LCMZBNO\`B?G_`(1B+T^TIG\F
MKG/'O_)8?!_U7_T8:[7QOISZGX5NHH4+S)MD15ZD@]/RS6^&DHUHM]S.LFZ;
M2///`F@_VSKBRS)FUM,2/D<,W\*_U_"O816/X5T-=!T.&V('G-^\F8=W/7\N
MGX5LU>,K^VJ-K9;$8>E[.%NHA(`))P*^8?B3XK;Q7XKFFC8FRMLP6P]5!Y;\
M3S],>E>X_$'7O[+T;[)`^+F\!08ZJG\1_I^-?/7B*P^S70GC7$<W7'9N]2L-
M-T?;=/ZU*]M'VGLROH&LS:!K5MJ-N-SPOED/213PRGV()'XUZ!JEM!!<)-9,
M7L+N,7%JY[QMV/NIRI^E>75WO@F__M?1KC0)3FYMMUU89ZL.LL0^H&X>X/K6
MN!Q'L:EGLS/$TN>%UNB>NU^%N?\`A(+OKC[-S_WT*XH<BO1?A78D1W]\PX8K
M"A]<<G^8KV,?)1P\KG!AE>JCT.BBBOFCV!KHLBE74,I&"",@BJL.CZ=;2B6W
MT^TBD'1TA52/Q`JY10`Q(HXRQ1%4L<G:,9IDUI;W&//@BEQTWH&Q^=344;!8
MBBMXH%VPQ1QCT10/Y5%<:98W<@DNK*VF<#`:2)6(_$BK5)0!1DO=/AU.WL9&
MB6[="T,97G:/3CCI4+^)=*2.YD:\39;2B&8@$[7)P!TY_"LKQ'I&H7.JC4-/
MA#SVT"-;DL`&<.<K^*DUER>%M0M],O+>&!I'>:UE#(ZAG*\R,">ASGK75"E2
M:3E+M^>IA*I--I(Z8>(=&B@-V)E2-Y/*W^2P+/C.,8R>*=#KNCFVDNX;B$1B
M18Y&"D$,3@`C&>2>]9%W::C+:Z=)'97LCVE^)F2XG1I&3:>ASCJ>E5]0T75-
M3-_>FS$,EQ);*EOYBEML;Y+,1QGGIZ"A4J;W?XKN#J3Z(W[_`%C2!<-87KQR
MR9&^(Q&0+GINP"!^-.BFT?2]233X$M;:[G7<L4<84N.?0>QK.L8M0T74=05=
M.>[AO+HSI/%(H(W8R&#$'C';-9MQX<U:[2ZU8R-'J1N!/#:_(5PAPBENHRN>
MAQS4JG3;U>GZ@ZDTMCK(;JTU#SXXRDWD2&.52N=KCG'/UJ=Y$MX6=L+'&I)/
M8`5S>DF_TJ\U)I]+G,-S=-<>:KH0BE1U&<\8/2MAI)-2T)Y%@DB>X@;;%)@,
M,@X!]#6<X<KTV-(SNO,8FL:3=7EI&L\+W%S%YUN"O+)Z@D>QITVNZ=!;//+=
M(L:2F$DYSO'!4#J3]*YJ'PK=W"6:S)]GFMM,B2*8,"8KA7R/_K^QHM-(UB*.
MRU&>QC>ZM[R>>6U$@^82<;E/3([9K9TJ727]?U]QE[2IV.ML;Z#4;?SK9BR9
M*Y9"IR/8@&I9ID@B>65@L:*69CT`'4U3M[Z[F\@OILT(D9@^^1,Q@#@G!.<]
M.*YCXF:K-:Z3'90HX2Z/[V4`[0H_ASZD_H*SI4G4J*"ZFDZG)!R9P/B'67U[
M6I[ULB,G;$I_A0=/\?QK$O[-;ZSD@;JPRI]#VJQ17TZIQ4/9VTV/&YWS<W4\
M^DC:*1D<893@CT-3:=?W&EZC;WMFYCN+>021MZ$'-=;<Z-9W<[32QMO;J5;&
M:=8^#H=2NEMK*UGFF;^%7/'N3V%>)/+:D;NZL>E'&0=E9W.@GM1K%Q8WFCQ9
MAU8;XHU_Y9R9Q)&?]TY_`BO9-#TF/1-(M[&(@B)?F;^\QY)_.L3P+X+B\(Z4
MT)D:6:5_-8$[EB8C!V_48R>^*ZNN>OB95(QIOI^)I2HQA)R74****Y3<****
M`"BBB@`HHHH`2C%%%`!BC%%%`!BBBB@`Q1110`48HHH`,4R:"*XB:*:-)(V&
M&5QD'\***`.6U#X<:+>,7MUEM&/:)LK^1S^E93?"B/=\NK.![P`G^=%%=$<;
M7BK*1B\/2>Z+EG\,-+A<-=7%S<X_AR$'Z<_K75Z?IEGI<'DV-M'`G<(,9^IZ
;FBBHJ5ZE7XY7*A2A#X46J6BBLC0****`/__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
